Terms: = Prostate cancer AND SUZ12, CHET9, 23512, ENSG00000178691, Q15022, KIAA0160, JJAZ1
31 results:
1. Race-specific coregulatory and transcriptomic profiles associated with DNA methylation and androgen receptor in prostate cancer.
Ramakrishnan S; Cortes-Gomez E; Athans SR; Attwood KM; Rosario SR; Kim SJ; Mager DE; Isenhart EG; Hu Q; Wang J; Woloszynska A
Genome Med; 2024 Apr; 16(1):52. PubMed ID: 38566104
[TBL] [Abstract] [Full Text] [Related]
2. PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing.
Fong KW; Zhao JC; Lu X; Kim J; Piunti A; Shilatifard A; Yu J
Mol Cell; 2022 Dec; 82(24):4611-4626.e7. PubMed ID: 36476474
[TBL] [Abstract] [Full Text] [Related]
3. Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant prostate cancer.
Han Z; Rimal U; Khatiwada P; Brandman J; Zhou J; Hussain M; Viola RE; Shemshedini L
Endocrinology; 2022 Nov; 164(1):. PubMed ID: 36288553
[TBL] [Abstract] [Full Text] [Related]
4. RNA-driven JAZF1-suz12 gene fusion in human endometrial stromal cells.
Gupta SK; Jea JD; Yen L
PLoS Genet; 2021 Dec; 17(12):e1009985. PubMed ID: 34928964
[TBL] [Abstract] [Full Text] [Related]
5. Low-grade endometrial stromal sarcoma-like tumors in male with JAZF1 gene fusions.
Dermawan JK; Zhang L; Singer S; Chi P; Antonescu CR
Genes Chromosomes Cancer; 2022 Feb; 61(2):63-70. PubMed ID: 34651371
[TBL] [Abstract] [Full Text] [Related]
6. Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes.
Acosta AM; Sholl LM; Dickson BC; McKenney JK; Gordetsky JB; Pins MR; Marino-Enriquez A; Dong F; Dubuc AM; Cin PD; Fletcher CDM
Mod Pathol; 2021 Sep; 34(9):1763-1779. PubMed ID: 33986460
[TBL] [Abstract] [Full Text] [Related]
7. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in cancer.
Martin MC; Zeng G; Yu J; Schiltz GE
J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
[TBL] [Abstract] [Full Text] [Related]
8. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
Gautam N; Kaur M; Kaur S
J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
[TBL] [Abstract] [Full Text] [Related]
9. Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer.
Shankar E; Franco D; Iqbal O; Moreton S; Kanwal R; Gupta S
Toxicol Appl Pharmacol; 2020 Oct; 404():115200. PubMed ID: 32805266
[TBL] [Abstract] [Full Text] [Related]
10. UHRF1 regulates CDH1 via promoter associated non-coding RNAs in prostate cancer cells.
Magnani E; Macchi F; Mancini M; Lomazzi V; Cogliati S; Pistore C; Mandruzzato M; Dock-Bregeon AC; Bonapace IM
Biochim Biophys Acta Gene Regul Mech; 2018 Mar; 1861(3):258-270. PubMed ID: 29466696
[TBL] [Abstract] [Full Text] [Related]
11. Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation.
Kedage V; Strittmatter BG; Dausinas PB; Hollenhorst PC
J Biol Chem; 2017 Oct; 292(42):17225-17235. PubMed ID: 28887309
[TBL] [Abstract] [Full Text] [Related]
12. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human prostate Carcinoma.
Anestopoulos I; Sfakianos AP; Franco R; Chlichlia K; Panayiotidis MI; Kroll DJ; Pappa A
Molecules; 2016 Dec; 22(1):. PubMed ID: 28042859
[TBL] [Abstract] [Full Text] [Related]
13. Mutations and deletions of PRC2 in prostate cancer.
Jain P; Di Croce L
Bioessays; 2016 May; 38(5):446-54. PubMed ID: 27000413
[TBL] [Abstract] [Full Text] [Related]
14. Analysis of interactions between the epigenome and structural mutability of the genome using Genboree Workbench tools.
Coarfa C; Pichot C; Jackson A; Tandon A; Amin V; Raghuraman S; Paithankar S; Lee AV; McGuire SE; Milosavljevic A
BMC Bioinformatics; 2014; 15 Suppl 7(Suppl 7):S2. PubMed ID: 25080362
[TBL] [Abstract] [Full Text] [Related]
15. The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer.
Chuang CH; Wang WJ; Li CF; Ko CY; Chou YH; Chuu CP; Cheng TL; Wang JM
Cell Death Dis; 2014 May; 5(5):e1220. PubMed ID: 24810056
[TBL] [Abstract] [Full Text] [Related]
16. ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.
Mochmann LH; Neumann M; von der Heide EK; Nowak V; Kühl AA; Ortiz-Tanchez J; Bock J; Hofmann WK; Baldus CD
Oncotarget; 2014 Jan; 5(2):351-62. PubMed ID: 24504051
[TBL] [Abstract] [Full Text] [Related]
17. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.
Deb G; Thakur VS; Gupta S
Epigenetics; 2013 May; 8(5):464-76. PubMed ID: 23644490
[TBL] [Abstract] [Full Text] [Related]
18. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer.
Kron K; Trudel D; Pethe V; Briollais L; Fleshner N; van der Kwast T; Bapat B
Clin Cancer Res; 2013 Jul; 19(13):3450-61. PubMed ID: 23549870
[TBL] [Abstract] [Full Text] [Related]
19. Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancer.
Mo W; Zhang J; Li X; Meng D; Gao Y; Yang S; Wan X; Zhou C; Guo F; Huang Y; Amente S; Avvedimento EV; Xie Y; Li Y
PLoS One; 2013; 8(2):e56592. PubMed ID: 23451058
[TBL] [Abstract] [Full Text] [Related]
20. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.
Duan Z; Zou JX; Yang P; Wang Y; Borowsky AD; Gao AC; Chen HW
Prostate; 2013 Apr; 73(5):455-66. PubMed ID: 23038103
[TBL] [Abstract] [Full Text] [Related]
[Next]
